Published in Clin Liver Dis on February 26, 2015
Hepatocellular carcinoma: Where are we? World J Exp Med (2016) 0.92
International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer (2016) 0.88
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030. J Clin Oncol (2016) 0.85
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Med (2016) 0.84
Hepatocellular carcinoma and the risk of occupational exposure. World J Hepatol (2016) 0.82
Sphingosine-1-phosphate induced epithelial-mesenchymal transition of hepatocellular carcinoma via an MMP-7/ syndecan-1/TGF-β autocrine loop. Oncotarget (2016) 0.81
Identification of novel long non-coding RNAs deregulated in hepatocellular carcinoma using RNA-sequencing. Oncotarget (2016) 0.81
Natural History of Nonalcoholic Fatty Liver Disease. Dig Dis Sci (2016) 0.80
Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells - evidence for a role in hepatocellular carcinoma growth in vivo. Mol Cancer (2016) 0.79
An updated dose-response meta-analysis of coffee consumption and liver cancer risk. Sci Rep (2016) 0.77
Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care. J Natl Cancer Inst (2015) 0.77
Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for U.S. Adults. Cancer Res (2016) 0.76
Pesticide exposure and liver cancer: a review. Cancer Causes Control (2017) 0.75
Editorial on "What is a potentially damaging vaccination delay in children younger than 2 years?" Hum Vaccin Immunother (2016) 0.75
Lipid rafts promote liver cancer cell proliferation and migration by up-regulation of TLR7 expression. Oncotarget (2016) 0.75
Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. Mediators Inflamm (2017) 0.75
Dietary restriction protects against diethylnitrosamine-induced hepatocellular tumorigenesis by restoring the disturbed gene expression profile. Sci Rep (2017) 0.75
Identification of MicroRNAs Involved in Growth Arrest and Apoptosis in Hydrogen Peroxide-Treated Human Hepatocellular Carcinoma Cell Line HepG2. Oxid Med Cell Longev (2016) 0.75
Clinical and biological significance of miR-23b and miR-193a in human hepatocellular carcinoma. Oncotarget (2016) 0.75
MiR-19a, miR-122 and miR-223 are differentially regulated by hepatitis B virus X protein and involve in cell proliferation in hepatoma cells. J Transl Med (2016) 0.75
Predictive factors in patients with hepatocellular carcinoma receiving sorafenib therapy using time-dependent receiver operating characteristic analysis. J Cancer (2017) 0.75
Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry. BMC Cancer (2015) 0.75
Higher Glucose and Insulin Levels Are Associated with Risk of Liver Cancer and Chronic Liver Disease Mortality among Men without a History of Diabetes. Cancer Prev Res (Phila) (2016) 0.75
Prognostic and Therapeutic Values of Tumor Necrosis Factor-Alpha in Hepatocellular Carcinoma. Med Sci Monit (2016) 0.75
COMMD7 is correlated with a novel NF-κB positive feedback loop in hepatocellular carcinoma. Oncotarget (2016) 0.75
Sphingosine kinase 1: A novel independent prognosis biomarker in hepatocellular carcinoma. Oncol Lett (2017) 0.75
The 50 Most-cited Articles in Gastroenterology and Hepatology from Mainland China. Pak J Med Sci (2017) 0.75
Hepatic Lesions Detected after Mastectomy, in Breast Cancer Patients with Hepatitis Background May Need to Undergo Liver Biopsy to Rule Out Second Primary Hepatocellular Carcinoma. PLoS One (2016) 0.75
Identification of serologic biomarkers for predicting microvascular invasion in hepatocellular carcinoma. Oncotarget (2016) 0.75
International incidence and mortality trends of liver cancer: a global profile. Sci Rep (2017) 0.75
Comparison of genome-scale DNA methylation profiles in hepatocellular carcinoma by viral status. Epigenetics (2016) 0.75
Multi-omics study revealing the complexity and spatial heterogeneity of tumor-infiltrating lymphocytes in primary liver carcinoma. Oncotarget (2017) 0.75
Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore) (2017) 0.75
Adiposity across the adult life course and incidence of primary liver cancer: The NIH-AARP cohort. Int J Cancer (2017) 0.75
Association between HLA-DQ Gene Polymorphisms and HBV-Related Hepatocellular Carcinoma. Gastroenterol Res Pract (2017) 0.75
Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy. Oncol Lett (2017) 0.75
Tooth loss and liver cancer incidence in a Finnish cohort. Cancer Causes Control (2017) 0.75
What is in a name? Does cancer subtyping help or hinder in epidemiology research? Eur J Epidemiol (2017) 0.75
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 37.89
Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract (2009) 25.83
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09
Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum (2004) 14.27
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol (2006) 10.21
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol (1993) 8.07
Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol (2004) 6.67
Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. IARC Monogr Eval Carcinog Risks Hum Suppl (1987) 6.47
Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine (2012) 6.01
Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J Clin Oncol (2013) 5.69
The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet (2000) 5.44
Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest (2009) 5.09
A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev (1994) 4.62
A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol (2005) 4.48
Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet (1992) 4.11
Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer (2009) 3.90
Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst (2012) 3.69
The epidemiology of obesity: the size of the problem. J Intern Med (2008) 3.62
The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology (2000) 3.53
Cancer risk among statin users: a population-based cohort study. Int J Cancer (2005) 3.50
The statins as anticancer agents. Clin Cancer Res (2003) 3.36
Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect (2010) 3.35
Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst (2009) 3.19
The natural history of chronic hepatitis B virus infection. Hepatology (2009) 3.08
Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol (2002) 2.94
Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem (2010) 2.87
Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology (2012) 2.74
Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol (2012) 2.66
45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med (2000) 2.66
Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis (2009) 2.62
Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf (2008) 2.43
Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology (2009) 2.39
Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology (2002) 2.38
Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis (2009) 2.38
Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology (2003) 2.38
Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev (2012) 2.38
Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer (2007) 2.23
Genetic history of hepatitis C virus in East Asia. J Virol (2008) 2.20
Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer (2004) 2.13
Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. Int J Epidemiol (2009) 2.11
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One (2013) 2.10
Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res (2000) 2.09
A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A (2002) 2.02
Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology (2009) 1.95
Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. Food Chem Toxicol (2002) 1.88
Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol (2013) 1.87
Systematic review: the association between obesity and hepatocellular carcinoma - epidemiological evidence. Aliment Pharmacol Ther (2010) 1.76
Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol (2012) 1.71
Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol (2014) 1.69
Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer (2011) 1.69
Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum (1997) 1.69
Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer (2000) 1.67
Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology (2003) 1.61
Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol (2011) 1.59
The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. J Clin Gastroenterol (2014) 1.57
Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol (2006) 1.56
The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol (2001) 1.48
Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev (2011) 1.44
A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int (2011) 1.43
Statin use and the risk of liver cancer: a population-based case–control study. Am J Gastroenterol (2010) 1.40
Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology (2002) 1.35
Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev (2000) 1.32
Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J Virol (2014) 1.27
Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol (2002) 1.26
An overview about hepatitis C: a devastating virus. Crit Rev Microbiol (2010) 1.23
Natural history of chronic hepatitis B. Clin Liver Dis (2010) 1.22
Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA (2013) 1.21
Dating the origin and dispersal of hepatitis B virus infection in humans and primates. Hepatology (2013) 1.19
Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med (2008) 1.16
Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand. Cancer Epidemiol Biomarkers Prev (2005) 1.15
Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev Res (Phila) (2013) 1.14
Investigating the endemic transmission of the hepatitis C virus. Int J Parasitol (2007) 1.14
Statins and primary liver cancer: a meta-analysis of observational studies. Eur J Cancer Prev (2013) 1.07
Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology (2014) 1.06
Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol (2013) 1.05
Statin use and risk of hepatocellular carcinoma. Eur J Epidemiol (2013) 1.04
Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Int J Cancer (2014) 1.04
Common cancer risk and statins: a population-based case-control study in a Chinese population. Expert Opin Drug Saf (2012) 1.02
Reconstructing the origins of human hepatitis viruses. Philos Trans R Soc Lond B Biol Sci (2001) 1.02
Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis. World J Gastroenterol (2005) 1.00
Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci (2004) 0.99
Epidemiological studies of the association between tea drinking and primary liver cancer: a meta-analysis. Eur J Cancer Prev (2011) 0.98
Control of hepatocellular carcinoma through hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention. Cancer Lett (2009) 0.98
Coffee: biochemistry and potential impact on health. Food Funct (2014) 0.98
Aspirin chemoprevention of gastrointestinal cancer in the next decade. A review of the evidence. Pol Arch Med Wewn (2010) 0.97
Coffee constituents as modulators of Nrf2 nuclear translocation and ARE (EpRE)-dependent gene expression. J Nutr Biochem (2010) 0.97
Declining rates of hepatocellular carcinoma in urban Shanghai: incidence trends in 1976-2005. Eur J Epidemiol (2011) 0.96
Chronic Japanese schistosomiasis and hepatocellular carcinoma: ten years of follow-up in Yamanashi Prefecture, Japan. Bull World Health Organ (1999) 0.95
Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Rev Clin Pharmacol (2010) 0.95
Lack of perinatal transmission of hepatitis B virus infection in Senegal, West Africa. J Pediatr (1985) 0.94
Coffee and liver diseases. Fitoterapia (2009) 0.89
Statin use and risk of hepatocellular carcinoma in a U.S. population. Cancer Epidemiol (2014) 0.89
Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. Ann Oncol (2014) 0.85
Determinants of formation of aflatoxin-albumin adducts: a seven-township study in Taiwan. Br J Cancer (2002) 0.84
Statin treatment reduces the risk of hepatocellular carcinoma but not colon cancer-results from a nationwide case-control study in Sweden. Pharmacoepidemiol Drug Saf (2014) 0.83
Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes. Br J Cancer (2014) 0.83
Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases: a meta-analysis of cohort studies. Eur J Cancer Prev (2015) 0.82
Cytidine deamination and cccDNA degradation: A new approach for curing HBV? Hepatology (2014) 0.81
Seroepidemiology of hepatitis B virus infection among adults in Singapore: a 12-year review. Vaccine (2013) 0.79